These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34031913)

  • 1. TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ma HL; Chen SD; Zheng KI; Yu Y; Wang XX; Tang LJ; Li G; Rios RS; Huang OY; Zheng XY; Xu RA; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2925-2934. PubMed ID: 34031913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variations of superoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholic steatohepatitis.
    Huang YS; Chang CH; Lin TL; Perng CL
    Liver Int; 2014 Jul; 34(6):931-6. PubMed ID: 24649902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 8. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.
    Bell LN; Molleston JP; Morton MJ; Klipsch A; Saxena R; Vuppalanchi R; Chalasani N
    J Clin Gastroenterol; 2011 Oct; 45(9):800-7. PubMed ID: 21602702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.
    Nelson JE; Handa P; Aouizerat B; Wilson L; Vemulakonda LA; Yeh MM; Kowdley KV;
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1253-1264. PubMed ID: 27730688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
    Chtioui H; Semela D; Ledermann M; Zimmermann A; Dufour JF
    Liver Int; 2007 Aug; 27(6):764-71. PubMed ID: 17617119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
    Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
    Surapaneni KM; Priya VV; Mallika J
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis.
    Zhang X; Shen J; Man K; Chu ES; Yau TO; Sung JC; Go MY; Deng J; Lu L; Wong VW; Sung JJ; Farrell G; Yu J
    J Hepatol; 2014 Dec; 61(6):1365-75. PubMed ID: 25048951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.
    Weltman MD; Farrell GC; Hall P; Ingelman-Sundberg M; Liddle C
    Hepatology; 1998 Jan; 27(1):128-33. PubMed ID: 9425928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP14 governs CYP2E1 to promote nonalcoholic fatty liver disease through deubiquitination and stabilization of HSP90AA1.
    Wei D; Tian X; Zhu L; Wang H; Sun C
    Cell Death Dis; 2023 Aug; 14(8):566. PubMed ID: 37633951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver.
    Gopal T; Kumar N; Perriotte-Olson C; Casey CA; Donohue TM; Harris EN; Talmon G; Kabanov AV; Saraswathi V
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G428-G438. PubMed ID: 31928222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study.
    Zhou J; Liu J; Sheng H; You N; Chen J; Mi X; Yang W; Zang S; Shi J;
    Adv Ther; 2019 Apr; 36(4):880-895. PubMed ID: 30820874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.